Deletion of Apoptosis Inhibitor of Macrophage (AIM)/CD5L Attenuates the Inflammatory Response and Infarct Size in Acute Myocardial Infarction

Toshiyuki Nishikido, MD; Jun-ichi Oyama, MD, PhD; Aya Shiraki, MD, PhD; Hiroshi Komoda, PhD; Koichi Node, MD, PhD

Background—An excessive inflammatory response after myocardial infarction (MI) increases myocardial injury. The toll-like receptor (TLR)-4 is activated by the recognition of endogenous ligands and is proinflammatory when there is myocardial tissue injury. The apoptosis inhibitor of the macrophage (AIM) is known to provoke an efflux of saturated free fatty acids (FFA) due to lipolysis, which causes inflammation via the TLR-4 pathway. Therefore, this study investigated the hypothesis that AIM causes a proinflammatory response after MI.

Methods and Results—The left anterior descending coronary artery was ligated to induce MI in both AIM-knockout (AIM−/−) and wild-type (WT) mice. After 3 days, the inflammatory response from activation of the TLR-4/NFκB pathway was assessed, and infarct size was measured by staining with triphenyltetrazolium chloride. In addition, left ventricular remodeling was examined after 28 days. Although the area at risk was similar between AIM−/− and WT mice, the infarct size was significantly smaller in AIM−/− mice (P=0.02). The heart weight–to–body weight ratio and myocardial fibrosis were also decreased in the AIM−/− mice, and the 28-day survival rate was improved (P<0.01). With the reduction of plasma FFA in AIM−/− mice, myocardial IRAK4 and NFκB activity were decreased (all P<0.05). Moreover, there was a reduction in myeloperoxidase activity and inducible nitric oxide synthase as part of the inflammatory response (P<0.01, P=0.03, respectively). Furthermore, NFκB DNA-binding activation via TLR-4, neutrophil infiltration, and inflammatory mediators were decreased in AIM−/− mice.

Conclusions—The deletion of AIM reduced the inflammatory response and infarct size and improved survival after myocardial infarction. (J Am Heart Assoc. 2016;5:e002863 doi: 10.1161/JAHA.115.002863)

Key Words: apoptosis inhibitor of macrophage • free fatty acids • inflammation • myocardial infarction • toll-like receptor-4

Myocardial infarction (MI) causes an inflammatory response that plays a crucial role in infarct repair and subsequent damage. However, excessive inflammation generates reactive oxygen species (ROS) in the injured myocardium, including complement initiation and neutrophil infiltration, which can trigger an inflammatory cascade through cytokine expression and direct damage of cardiac myocytes. Therefore, it is important to prevent activation of radical inflammatory pathways to reduce infarct size and promote cardiac repair, which can preserve cardiac function.

Apoptosis inhibitor of the macrophage (AIM)/CD5L protein is a member of the scavenger receptor cysteine-rich domain superfamily (SRCR-SF), which directly inhibits apoptosis of macrophages. Furthermore, AIM is also a direct target for antiapoptotic regulation by LXR/RXR heterodimers. AIM was shown to induce an efflux of saturated free fatty acids (FFAs), such as palmitic and stearic acid, due to lipolysis in obese adipose tissue, which leads to the production of inflammatory cytokines and neutrophil recruitment through toll-like receptor (TLR)-4 activation. This can lead to chronic and sustained inflammation, which is closely associated with insulin resistance and progression of atherosclerosis and contributes to future cardiovascular events. In chronic inflammation due to AIM, the TLR-4/nuclear factor-kappa B (NFκB) pathway, activated by endogenous extracellular FFAs, plays an important role in the development of inflammation.

TLR-4 is activated by the recognition of not only pathogen-associated molecular patterns, such as bacterial lipopolysaccharide (LPS), but also endogenous host-derived ligands including heat shock protein 60 (HSP60), high-mobility group

From the Departments of Cardiovascular Medicine (T.N., A.S., H.K., K.N.) and Advanced Cardiology (J.O.), Saga University, Saga, Japan.

Correspondence to: Jun-ichi Oyama, MD, PhD, Department of Advanced Cardiology, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan. E-mail: junoyama@cc.saga-u.ac.jp

Received October 28, 2015; accepted February 19, 2016.
AIM and Myocardial Infarction  Nishikido et al

box 1 (HMGB-1), extracellular degradation products of the extracellular matrix (ECM), and free fatty acids (FFA) in innate immunity.14–16,18–22

They are produced as a result of cell death or injury, which stimulates cell surface TLRs, resulting in an inflammatory response. Our previous studies as well as studies by other investigators demonstrated that TLR-4 is involved in the proinflammatory response to ischemic myocardial tissue injury without the need for any microbial pathogens.23,24

However, it is still unclear what triggers this response and enhances the inflammatory signals including TLR-4 signaling in MI. Therefore, deletion of AIM can decrease FFA and may reduce the signaling through TLR-4 in the process of myocardial injury. Based on this hypothesis, we investigated whether the deletion of AIM affects the degree of myocardial damage or the inflammatory response following myocardial injury using AIM knockout (AIM−/−) mice.

Methods

Experimental Animals

AIM−/− mice were obtained from Prof Toru Miyazaki at Tokyo University. The AIM−/− mice were generated by the targeting vector that was prepared using a 7-kb SpeI-BamHI fragment. It was inserted into the disrupted Ncol site in exon 3, which encodes the second SRCR domain.25 AIM−/− without the recognition sequence of BamHI was confirmed using cutting by a BamHI restriction enzyme and agarose gel electrophoresis. The primer used had the following sequences: F, AIM4000F 5'-AAT GGT TCT TCA TAT AGC TTT GGT-3'; R, AIM4400R 5'-GAT GTG GTA CAT ATA CAC AGA TCT-3'. Moreover, we confirmed no AIM protein expression by Western blotting. AIM−/− mice had been backcrossed to C57BL/6 for at least 13 generations before being used for experiments.

The C57BL/6 mice, which were used as a control group, were purchased from Kyudo Co, Ltd (Tosu, Japan). Animals were housed in a specific pathogen-free environment. All experiments were performed in accordance with the “Position of the American Heart Association on Research Animal Use” and Saga University Standing Committee rules on animal research.

Surgery to Achieve Myocardial Infarction

Mice (aged 12–16 weeks) were anesthetized with ketamine (100 mL/kg) and xylazine (10 mg/kg) and intubated for mechanical ventilation. A left thoracotomy was performed to expose the heart, and MI was achieved by ligation of the left anterior descending coronary artery using an 8-0 silk suture. After the chest wall was closed, the mice were extubated, and the hearts were harvested at 3 and 28 days after surgery.

Measurement of Infarct Size

The mice were anesthetized as described above at 3 days, and a catheter was inserted into the aortic root via the internal carotid artery. Then, 1% Evans blue was infused into the aorta and coronary arteries to assess the area at risk. The hearts were sliced transversely into 2-mm-thick sections and incubated with 1% triphenyltetrazolium chloride solution (TTC) (Sigma Aldrich Chemical, Buchs, Switzerland) at 37°C for 15 minutes, as previously described.23 The viable myocardium was stained brick red by the TTC, the area at risk (AAR) was the myocardial tissue not stained by Evan’s blue, and the infarct area was that portion of the AAR that was not stained by TTC. The AAR and infarct size (IS) were measured in each section using Image J software.

Echocardiography and Hemodynamic Analysis

Echocardiographic analysis was performed at 28 days using an echocardiographic machine with a 15-MHz transducer (Toshiba, Tokyo, Japan). From 2-dimensional echocardiography in the short-axis view, the left ventricular end-diastolic diameter (LVEDD) and end-systolic diameters (LVESD) were measured, and fractional shortening (%FS) was calculated as [(LVEDD–LVESD)/LVEDD × 100], as previously described.23 A 1.2 Fr catheter (Transonic Systems Inc, Ithaca, NY) was inserted into the left ventricle through the right carotid artery, and the hemodynamic values were measured.

Histological Analysis

Samples were taken from cardiac tissue around the infarct region and fixed in 4% formalin for 24 hours before cryopexy. Left ventricular sections (5 μm) were stained with hematoxylin-eosin. In addition, the collagen density was assessed using Masson trichrome stain, as previously described.23 The total area of fibrosis was analyzed quantitatively using a BZ-X710 all-in-one microscope (KEYENCE, Osaka, Japan). In immunohistochemistry stains using the neutrophil-specific maker Gr-1 (Ly-6G; #550291, 1:10, BD BioScience, SanJose, CA), we analyzed neutrophil infiltrations on hearts from 3 mice in each group. Secondary antibodies consisted of biotinylated anti-rat antibodies, followed with streptavidin-peroxidase staining kit (Histofine Simple Stain MaxPO Multi, Nichirei, Tokyo, Japan) and visualized with a peroxidase substrate solution containing 3,3′-diaminobenzidine (Simple Stain DAB, Nichirei, Tokyo, Japan).

Myocardial Myeloperoxidase Activity Assay

The myocardial myeloperoxidase (MPO) activity was measured as an index of myocardial neutrophil infiltration with the
Neutrophil Myeloperoxidase Activity Assay Kit (#600620, Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s instructions.  

Thiobarbituric Acid Reactive Substances Assay  
Lipid peroxidation is a mechanism of cell damage by reactive oxygen species derived from polyunsaturated fatty acids, and thiobarbituric acid reactive substances (TBARS) are end products of the lipid peroxidation. We measured TBARS levels as an index of oxidative stress with myocardial tissues using The OxiSelect™ TBARS Assay kit (STA-330, Cell Biolabs, San Diego, CA).

Western Immunoblotting Assay  
Heart sections were homogenized in cytoplasmic and nuclear extraction regents (Thermo Scientific, Hudson, NH) containing protease inhibitors. Samples of myocardium lysate were resolved on SDS-PAGE according to a standard protocol. After transfer to membranes, the samples were immunoblotted with primary antibodies followed by secondary antibodies conjugated to horseradish peroxidase, and bands developed with enhanced chemiluminescence was conducted using ECL Plus Western Blotting Detection Regents (GE Healthcare, Buckinghamshire, UK). Enhanced chemiluminescence was detected with an LAS-3000 image analyzer (Fujifilm, Tokyo, Japan), and band density was quantified using Image J software. The following primary antibodies were used: NFκB p65 (sc-372, 1:1000) (BD Transduction Laboratories, Lexington, KY), iNOS (sc-168, 1:1000), Histon H1 AE-4 (sc-8030, 1:500) (Santa Cruz Biotechnology, Santa Cruz, CA), and β-actin (A5458, 1:5000) (Cell Signaling Technology, Danvers, MA). The following secondary antibodies were used: anti-rabbit IgG HRP (sc-2004, 1:1000) and anti-mouse IgG HRP (sc-2005, 1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA). Band density was measured using Image J software.  

Nuclear Factor-kB Activity Analysis  
The DNA-binding activity of NFκB p65 was measured from the nuclear extract using a TransAM NFκB Transcription Factor ELISA Kit, according to the manufacturer’s protocol (Active Motif, Carlsbad, CA).

Plasma Free Fatty Acid Assay  
The concentrations of plasma FFAs were determined by using the EnzyChrom Free Fatty Acid Assay Kit (BioAssay Systems, Hayward, CA). The FFA was enzymatically converted to acyl-CoA and subsequently to H₂O₂, and FFA concentrations were measured using a colorimetric procedure for H₂O₂.

Statistical Analysis  
Data are expressed as mean±SEM. Comparisons between the groups were made using a 2-way analysis of variance (ANOVA), Tukey post hoc test. A P-value <0.05 was deemed statistically significant. Survival rates were analyzed by the Kaplan–Meier method. There was no adjustment for multiple endpoints. All statistical analyses were performed using the statistics package of SPSS software (version 22; IBM SPSS, Chicago, IL).

Results  
Reduced Myocardial Infarct Size in AIM Knockout Mice  
The deletion of AIM was confirmed using gel electrophoresis and Western blotting in AIM−/− mice (Figure 1A). On day 3 after MI, the AAR/LV was not different between the AIM−/− and WT mice (AAR/LV; 43.2±1.5% vs 40.8±2.3%; P=0.56). However, the IS/LV and IS/AAR were significantly smaller in AIM−/− than in WT mice (IS/LV; 20.8±0.6% vs 27.8±1.9%; P=0.02, IS/LV; 8.5±0.1% vs 11.1±0.9%; P=0.02) (Figure 1B). The survival rate at 28 days after MI in AIM−/− mice was significantly greater than that in WT mice (80.0% vs 40.0%, respectively; P=0.039) (Figure 1C).

We evaluated the influence of AIM−/− deletion on cardiac dysfunction after 28 days. The reduction in %FS in the AIM−/− mice was not as remarkable as that in WT mice. In hemodynamic analyses, systolic blood pressure and positive dp/dt after MI were higher in the AIM−/− mice than in WT mice after MI (P=0.02) (Figure 2A and 2B). These findings indicate that the deletion of AIM led to a reduction in infarct size and systolic dysfunction and to less subsequent myocardial remodeling. Myocardial infarction elicits an intense inflammatory response with ROS and neutrophil infiltration. Neutrophils and monocytes have abundant MPO, and MPO-derived ROS damages myocardial tissue.  

The Effect of AIM Deletion on Inflammation via the TLR-4/NFκB Pathway  
Previously, it was shown that AIM-induced lipolysis provokes an efflux of FFAs in adipose tissue, which activates the TLR-4 pathway and causes chemokine production. Therefore, we examined whether the inflammatory response via the TLR-4 pathway was attenuated after MI in AIM−/− mice, because we have shown previously that TLR-4 deficiency reduces the...
inflammatory response that is associated with expansion of myocardial injury after myocardial ischemia reperfusion. In AIM⁻/⁻ mice, plasma FFAs were decreased as compared with WT mice after 3 days, although there was no difference in baseline FFAs (224.1±11.6 μmol/L vs 299.7±16.2 μmol/L; P<0.01) (Figure 3A). In addition, we measured cytoplasmic fatty acid synthase (FAS) expression with Western blotting, and cytoplasmic FAS expression was increased in the AIM⁻/⁻ mice (P=0.04) (Figure 3B).

After MI, the NF-κB activity in myocardial nuclear extracts was significantly less in AIM⁻/⁻ than in WT mice (P<0.01), and NF-κB p65 protein expression in Western blot analysis was decreased in spite of there being no significant difference between the 2 groups before MI (P=0.04) (Figure 3C and 3D). In addition, IL-1 receptor-associated kinase (IRAK)-4, which is essential for NFκB activation in TLR-4–mediated signal transduction, was also significantly less in AIM⁻/⁻ mice than in WT mice (P=0.02) (Figure 3E). In AIM⁻/⁻ mice, the reduction in IRAK-4 linked to NFκB may mean less inflammation via the TLR-4/NFκB pathway after left anterior artery ligation. We next examined whether the reduction of activation of the TLR-4/NFκB pathway led to suppression of cytokine production. Inducible nitric oxide synthase (iNOS) induced by inflammatory cytokines produces a high level of nitric oxide and causes myocardial damage through ROS such as peroxynitrate, although this plays a beneficial role in the early defensive inflammatory response against reperfusion injury. After MI, iNOS expression was significantly decreased in AIM⁻/⁻ mice compared with WT mice (P=0.03) (Figure 3F). Therefore, in summary, the reduction of plasma FFAs by AIM deletion attenuated the inflammatory response via TLR-4 activation after MI, and this subsequently improved cardiac function and the survival rate (Figure 4).

Discussion

We demonstrated that the deletion of AIM reduced infarct size and the inflammatory response due to neutrophil infiltration after coronary artery ligation in mice. This decreased inflammatory response resulted in a reduction in interstitial fibrosis, heart weight, and the magnitude of cardiac remodeling, and this subsequently improved the survival rate. It suggested that AIM played an important role for the sustained inflammation and the progression of cardiac remodeling after MI.

Figure 1. A, AIM knockout (AIM⁻/⁻) mice without the recognition sequence of BamHI were confirmed using cutting by a BamHI restriction enzyme in gel electrophoresis. PCR product (400 bp) amplified from the AIM⁻/⁻ allele was not digested, yielding only the 400-bp band, whereas the wild-type (WT) allele was digested into 100+300 bp. B, Myocardial infarct (MI) size and area at risk after MI between AIM⁻/⁻ (n=8) and WT mice (n=8). The blue area is perfused tissue, the red and white area is the area at risk (AAR), and the white area is infarcted tissue (IS). The graphs show the IS as a percentage of the left ventricular (LV) area (IS/LV), the AAR as a percentage of LV area (AAR/LV), and IS as a percentage of AAR (IS/AAR). C, Kaplan-Meier survival estimates in AIM⁻/⁻ MI mice (n=15) and WT MI mice (n=15) 28 days after MI. All of AIM⁻/⁻ Sham mice (n=15) and WT Sham mice (n=15) survived. AIM indicates apoptosis inhibitor of the macrophage. *P<0.05.
AIM and TLR-4 Signaling in MI

Irreversible ischemic injury after MI results in myocardial necrosis, which prolongs and expands the inflammatory response. The deleterious signals released from necrotic cells and the extracellular matrix amplify the inflammatory response by activation of TLR signaling. Several studies have shown that TLR-4 signaling is activated by cardiac injury, which promotes an inflammatory cascade through the TLR-4/NFκB pathway. Previously, we demonstrated that TLR-4 caused a proinflammatory response that expanded myocardial injury after myocardial ischemia-reperfusion. This proinflammatory response included complement initiation, neutrophil infiltration, and ROS generation. Deficient mice exhibited a smaller infarct size with suppression of inflammatory reactions and less adverse remodeling following MI. However, the trigger of this response is unknown, and it is also not clear what activated TLR4 signaling after MI.

On the other hand, AIM provokes release of FFAs due to lipolysis from adipose tissue via CD36-mediated endocytosis, and FFAs play a major role in the activation of NFκB via the TLR-4 pathway as the endogenous ligand in a chronic inflammatory state. Our results suggested that NFκB and IRAK-4 in the TLR-4/NFκB pathway were activated after coronary ligation, but there was less of a response in AIM−/− mice compared with WT mice. As the infiltration of neutrophils and subsequent production of ROS expand myocardial tissue injury, the activities of MPO and iNOS were also decreased in AIM−/− mice after MI. The kinase activity of IRAK-4 was reported to be essential for regulation of a TLR-4–mediated innate immune response, leading to activation of NFκB in MyD88, dependent and independent of the signaling pathway. The suppression of the TLR-4/NFκB inflammatory cascade via IRAK-4 resulted in less activity of MPO and iNOS in mice that lacked AIM. These data suggest that the smaller infarct size and attenuation of cardiac remodeling reflected the suppression of inflammation after MI in AIM−/− mice. We thought that the increase in plasma FFAs due to AIM might have activated a proinflammatory response via the TLR-4 pathway after MI. Otherwise, in the presence of neutrophil infiltration and cytokine expression due to AIM via TLR-4, it is possible that the endogenous deleterious signals including HSP 60, HMGB-1, and ECM-derived components caused a stronger inflammatory response via the same TLR-4 pathway responsible for neutrophil infiltration after MI.

Role of Fatty Acids in Myocardial Ischemia

The major energy source of myocardium depends on the production of adenosine triphosphate (ATP) via oxidation of FFAs rather than glucose in aerobic metabolism; however, ATP production shifts more to glycolysis in the anaerobic state that develops during myocardial ischemia, which results in increasing lactate and cytoplasmic calcium leading to the impaired generation of ATP. Furthermore, catecholamine stimulation during myocardial ischemia increases the concentration of circulating FFAs as a result of lipolysis with the breakdown of triglycerides into FFAs and glycerol by catecholamine-sensitive lipase in adipose tissue. The ischemic myocardium is exposed to hypoxia due to excessive

Table. Differences in Echo Parameters, Hemodynamics, and Cardiac/Body Weights between AIM Knockout (AIM−/−) Mice and Wild-Type (WT) Mice after 28 Days

| Parameter          | AIM−/− Sham | AIM−/− MI | WT+ Sham | WT+ MI |
|--------------------|-------------|-----------|----------|--------|
| BW, g              | 28.0±0.5    | 28.3±0.5  | 28.9±0.6 | 29.7±0.8 |
| HW, mg             | 185.7±8.0   | 222.3±17.5*| 176.1±12.4 | 283.0±16.4† |
| HW/BW, mg/g        | 6.62±0.23   | 7.85±0.55† | 6.07±0.38 | 9.52±0.55† |
| HR, bpm            | 477.4±23.4  | 473.±16.2 | 454.1±14.0 | 439.0±26.4 |
| Systolic BP, mm Hg | 91.0±7.5    | 94.9±2.7† | 104.2±7.5 | 78.8±3.0 |
| Max dp/dt          | 4573.2±86.3 | 4066.7±148.7† | 5089.2±577.4 | 3492.3±199.9† |
| LVDd, mm           | 3.24±0.29   | 3.60±0.19 | 3.29±0.11 | 3.61±0.14 |
| LVd, mm            | 2.06±0.23   | 2.48±0.22 | 2.21±0.08 | 2.88±0.14 |
| IVS, mm            | 0.81±0.09   | 0.81±0.04 | 0.84±0.07 | 0.83±0.04 |
| PW, mm             | 0.79±0.04   | 0.85±0.06 | 0.78±0.05 | 0.76±0.03 |
| FS, %              | 32.5±1.18   | 28.4±2.58† | 34.8±1.4 | 20.5±1.4† |

AIM indicates apoptosis inhibitor of the macrophage; bpm, beats/min; BW, body weight; FS, ratio of left ventricular fractional shortening; HR, heart rate; HW, heart weight; IVS, thickness of interventricular septum; LVDd, diastolic dimension of left ventricle; LVd, systolic dimension of left ventricle; MI, myocardial infarction; PW, thickness of posterior wall.

*P<0.05 vs WT+MI.
†P<0.05 vs AIM−/− Sham.
Figure 2. A, The histological sections of hearts from AIM knockout (AIM<sup>−/−</sup>) mice (n=4) and wild-type (WT) mice (n=4) after myocardial infarction (MI). Each section was stained with hematoxylin-eosin (HE), and Masson trichrome (MT) stains. Sections were stained with Gr-1 antibody as a neutrophil-specific marker. B, The fibrosis was measured by quantitation with Masson trichrome staining. C, Myeloperoxidase (MPO) activity in hearts from AIM knockout (AIM<sup>−/−</sup>) mice and wild-type (WT) mice. Units of MPO activity in hearts were expressed as units per 100 mg tissue weight. D, Lipid peroxidation products malondialdehydes (MDA) as an index of oxidative stress. Units were nanomole per milligram of protein. AIM indicates apoptosis inhibitor of the macrophage. *P<0.05.
Figure 3. A, Serum concentrations of free fatty acid (FFA) were expressed. B, Fatty acid synthase (FASN) in hearts from AIM⁻/⁻ mice and wild-type (WT) mice measured by Western blot analysis. C, NFκB activity was measured by NFκB DNA binding assay. D, NFκB activity was quantified by Western blot analysis. E, Interleukin receptor-associated kinase 4 (IRAK4) was measured by Western blot analysis. F, Inducible nitric oxide synthase (iNOS) was measured by Western blot analysis. All data without serum FFA concentrations were obtained in hearts from AIM⁻/⁻ mice and WT mice after myocardial infarction (MI) 3 days. AIM indicates apoptosis inhibitor of the macrophage. *P<0.05.
oxygen consumption during FFA metabolism, which reduces the myocardial uptake of glucose that is required for anaerobic glycolysis and mitochondrial ATP production. The excessive uptake of FFAs into myocardium contributes to cardiac function impairment in the ischemic process, which can subsequently increase infarct size and mortality. We demonstrated that the circulating FFAs in AIM knockout (AIM−/−) mice were significantly lower in AIM−/− mice than WT mice after MI, and the release of FFAs was attenuated with an increase of FAS in AIM−/− mice. The reduced concentration of FFAs in AIM−/− mice not only was caused by the reduction of lipolysis, despite the activation of FAS through incorporation of AIM into adipocytes at baseline, but also might have been influenced by the inactivation of catecholamine-sensitive lipase due to a reduction in catecholamine concentrations. On the other hand, the activation of FAS, together with a decrease in FFAs, was observed in AIM−/− mice. It was reported that the inhibition of FAS activity due to AIM caused lipolysis in adipocytes without the activation of the cAMP/AMPK signaling pathway, hormone-sensitive lipase, and adipose triglyceride lipase. Although it is known that there is an important interaction between AIM and FAS, the FAS activity might be attenuated by negative feedback from the increase in FFAs after MI.

Finally, remodeling is correlated with infarct size and impairs cardiac function after MI, which can lead to heart failure and an increase in mortality during the chronic phase. TLR-4 plays important roles in inflammation and matrix turnover and contributes to LV healing and remodeling in animal models of MI. These findings are consistent with our results of less depression of LV contractility, suppression of interstitial fibrosis, reduced heart weight, and an improved survival rate in AIM−/− mice compared with WT mice. These beneficial effects were due to a reduction of the inflammatory response via the TLR-4 pathway.

Limitations

The deleterious signals including HSP60, HMGB-1, and ECM are known to activate the inflammatory response as ligands for TLR-4. It was possible in this present study that these deleterious signals increased after myocardial injury and produced a much stronger inflammatory response. However, we demonstrated a reduced FFA concentration and inflamma-

Figure 4. A diagram that shows less inflammation is associated with expansion of cardiac injury by AIM deletion after myocardial infarction (MI). AIM knockout (AIM−/−) mice have decreased free fatty acids (FFA) due to lipolysis, which leads to TLR-4 inactivation and the subsequent suppression of inflammation. AIM indicates apoptosis inhibitor of the macrophage; IRAK4, Interleukin receptor-associated kinase 4; LV, left ventricular; MPO, myocardial myeloperoxidase; NFκB, nuclear factor-κB; ROS, reactive oxygen species; TLR4, Toll-like receptor-4.
matory response after MI, and this subsequently reduced the infarct size in AIM$^{-/-}$ mice. Therefore, these results provide evidence for the proinflammatory effects of AIM, which might be useful for the treatment of MI in the future.

**Conclusion**

In summary, AIM-deficient mice demonstrated a smaller infarct size and less of an inflammatory response via inflammatory pathways after MI. These data provide the first evidence that AIM plays an important role in the inflammatory responses after myocardial injury. Therefore, the inhibition of AIM can prevent not only cardiovascular disease in chronic inflammation but also functional impairment after MI.

**Acknowledgments**

We thank Toru Miyazaki, Satoko Arai (Tokyo University), and Masaki Ohmuraya (Kumamoto University) for helpful advice. We also thank Masami Haraguchi, Ruriko Imaizui, and Haruna Nagao for their technical assistance.

**Sources of Funding**

Jun-ichi Oyama belongs to the endowed Department of Fukuda Denshi Co, Ltd. Koichi Node received remuneration including lecture fees from AstraZeneca, Astellas Pharma Inc, Nippon Boehringer Ingelheim Co, Ltd, Pfizer Inc., MSD K.K., Daiichi Sankyo Company, Ltd, Kowa Pharmaceutical Co, Ltd, Takeda Pharmaceutical Co., Ltd., Novartis Pharmaceuticals Japan, Mitsubishi Tanabe Pharma Corporation, and Dainippon Sumitomo Pharma Co., Ltd. Koichi Node also received scholarship funds or donations granted by Astellas Pharma Inc, Nippon Boehringer Ingelheim Co, Ltd, Daiichi Sankyo Company, Ltd, Takeda Pharmaceutical Co, Ltd, Mitsubishi Tanabe Pharma Corporation, and MSD K.K.

**Disclosures**

None.

**References**

1. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. *Cardiovasc Res*. 2002;53:1–47.
2. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. *Cardiovasc Res*. 1994;28:1301–1311.
3. Mehta JL, Li DY. Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain? *Cardiovasc Res*. 1999;43:291–299.
4. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. *J Hypertens*. 2000;18:655–673.
5. Dhalla NS, Elmoselhi AB, Hata T, Makino N. Status of myocardial antioxidants in ischemia-reperfusion injury. *Cardiovasc Res*. 2000;47:446–456.
6. Vakeva AP, Agah A, Rollins SA, Matsis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-CS therapy. *Circulation*. 1998;99:2259–2267.
7. Weisman HF, Bartos T, Leppo MK, Marsh HC Jr, Carson GR, Concco MF, Boyle MF, Roux KH, Weisfledt ML, Fearon DT. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. *Science*. 1990;249:146–151.
8. Entman ML, Youker K, Shoji T, Kukielka G, Shappell SB, Taylor AA, Smith CW. Neutrophil induced oxidative injury of cardiac myocytes. A compartmented system requiring CD11b/CD18-ICAM-1 adherence. *J Clin Invest*. 1992;90:1335–1345.
9. Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogeness J, O’Connell RM, Cheng G, Saez E, Miller JF, Tontonoz P. LXR-dependent gene expression is important for macrophage survival and the innate immune response. *Cell*. 2004;119:299–309.
10. Kurokawa J, Arai S, Nakashima K, Nagano H, Nishijima A, Miyata K, Ose R, Morii M, Kubota N, Kadowaki T, Oike Y, Koga H, Fabbriano M, Iwanaga T, Miyazaki T. Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. *Cell Metab*. 2010;11:479–492.
11. Kurokawa J, Nagano H, Ohara O, Kubota N, Kadowaki T, Arai S, Miyazaki T. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. *Proc Natl Acad Sci USA*. 2011;108:12072–12077.
12. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. *Arterioscler Thromb Vasc Biol*. 2005;25:2062–2068.
13. Miyazaki T, Kurokawa J, Arai S. AIMing at metabolic syndrome. Towards the development of novel therapies for metabolic diseases via apoptosis inhibitor of macrophage (AIM). *Circ J*. 2011;75:2522–2531.
14. Jialal I, Kaur H, Devaraj S. Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. *J Clin Endocrinol Metab*. 2014;99:39–48.
15. Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, Kotani H, Yamaoka S, Miyake K, Aoe S, Saito K, Ogawa Y. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. *Arterioscler Thromb Vasc Biol*. 2007;27:84–91.
16. Lee JY, Sohn KH, Rhie SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated inflammatory changes in the interaction between adipocytes and macrophages. *Arterioscler Thromb Vasc Biol*. 2007;27:84–91.
17. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freundenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in the Tlr4 gene. *Science*. 1998;282:2085–2088.
18. Tian J, Guo X, Liu XM, Liu L, Weng QF, Dong SJ, Knowlton AA, Yuan WJ, Lin L. Extracellular HSP60 induces inflammation through activating and up-regulating TLRs in cardiomyocytes. *Cardiovasc Res*. 2013;98:391–401.
19. Vabulas RM, Ahmad-Nejad P, da Costa C, Mietzke T, Kirschning CJ, Hacker H, Wagner H. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. *J Biol Chem*. 2001;276:31332–31339.
20. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. *J Immunol*. 2000;164:558–561.
21. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. *J Biol Chem*. 2004;279:7370–7377.
22. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF III. The extra domain A of fibronectin activates Toll-like receptor 4. *J Biol Chem*. 2001;276:10229–10233.
23. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. *Circulation*. 2004;109:784–789.
24. Timmers L, Stuipier JP, van Keulen JK, Hoef er I, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pastorink G, de Kleijn DP. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. *Circ Res*. 2008;102:257–264.
25. Miyazaki T, Hirokami Y, Matsuhashi N, Takatsuka H, Naito M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. *J Exp Med*. 1999;189:413–422.
26. Go LO, Murry CE, Richard VJ, Weischedel GR, Jennings RB, Reimer KA. Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury. *Am J Physiol*. 1988;255:H1168–H1199.
27. Suzuki N, Saito T. IRAK-4—a shared NF-kappaB activator in innate and acquired immunity. Trends Immunol. 2006;27:566–572.

28. Feng Q, Lu X, Jones DL, Shen J, Arnold JM. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation. 2001;104:700–704.

29. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;108:1133–1145.

30. Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefler IE, Dovendans PA, Pasterkamp G, de Kleijn DP. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation. 2010;121:80–90.

31. Riad A, Jager S, Sobirey M, Escher F, Yaulema-Riss A, Westermann D, Karatas A, Heimesaat MM, Bereswill S, Pauschinger M, Schultheiss HP, Tschope C. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol. 2008;180:6954–6961.

32. Suzuki N, Suzuki S, Yeh WC. IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol. 2002;23:503–506.

33. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007;13:460–469.

34. Cruickshank EJ, Kosterlitz HW. The utilization of fat by the aglycaemic mammalian heart. J Physiol. 1941;99:208–223.

35. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol. 2000;95:75–83.

36. Opie LH. The mechanism of myocyte death in ischaemia. Eur Heart J. 1993;14 (suppl G):31–33.

37. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res. 1997;33:243–257.

38. Opie LH. Metabolism of free fatty acids, glucose and catecholamines in acute myocardial infarction. Relation to myocardial ischemia and infarct size. Am J Cardiol. 1975;36:938–953.

39. Mjos OD, Kjekshus JK, Lekven J. Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. J Clin Invest. 1974;53:1290–1299.

40. Katz AM, Messineo FC. Lipid-membrane interactions and the pathogenesis of ischemic damage in the myocardium. Circ Res. 1981;48:1–16.

41. Oliver MF. Control of free fatty acids during acute myocardial ischaemia. Heart. 2010;96:1883–1884.

42. Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab. 2012;15:805–812.

43. Vik-Mo H, Mjos OD. Influence of free fatty acids on myocardial oxygen consumption and ischemic injury. Am J Cardiol. 1981;48:361–365.